Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
9948 patients were included in this systematic review and meta-analysis.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[RESULTS] A total of 71 studies comprising 9948 patients were included in this systematic review and meta-analysis.
[PURPOSE] Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is emerging as an imaging modality with an established role for assessment of prostate cancer.
- 95% CI 48-58
- 연구 설계 systematic review
APA
Zhu G, Xiong X, et al. (2026). Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis.. International urology and nephrology. https://doi.org/10.1007/s11255-026-05109-0
MLA
Zhu G, et al.. "Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis.." International urology and nephrology, 2026.
PMID
41872648 ↗
Abstract 한글 요약
[PURPOSE] Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is emerging as an imaging modality with an established role for assessment of prostate cancer. This review aims to evaluate the impact of PSMA PET on the management and clinical outcomes in men with biochemical failure of prostate cancer.
[METHODS] We conducted a comprehensive literature search of the electronic databases from inception to August, 2025. The outcomes of interest included prostate-specific antigen (PSA) responses, biochemical recurrence-free survival (BRFS), biochemical progression-free survival (BPFS), and overall survival (OS). Meta-regression and subgroup analyses were conducted to explore the heterogeneity. Sensitivity analysis was performed to assess the robustness of the results.
[RESULTS] A total of 71 studies comprising 9948 patients were included in this systematic review and meta-analysis. The pooled proportion of patients experiencing a management change following PSMA PET was 53% (95% CI: 48-58%). A decrease in serum PSA level was observed in 75% (95% CI: 65-85%) of patients. For survival outcomes, the pooled estimates for 1-, 2-, and 3-year biochemical recurrence-free survival (BRFS) were 62% (95% CI: 52-71%), 66% (95% CI: 55-77%), and 62% (95% CI: 46-78%), respectively. The corresponding estimates for biochemical progression-free survival (BPFS) were 77% (95% CI: 65-88%), 84% (95% CI: 71-97%), and 79% (95% CI: 61-96%), respectively.
[CONCLUSIONS] This meta-analysis suggests that PSMA PET-guided management is associated with favorable oncologic outcomes in men with biochemical recurrence, with over half of patients experiencing a change in management strategy and a substantial proportion demonstrating a biochemical response. Nevertheless, due to considerable heterogeneity across studies, these conclusions remain preliminary and require confirmation through more robust prospective evidence.
[METHODS] We conducted a comprehensive literature search of the electronic databases from inception to August, 2025. The outcomes of interest included prostate-specific antigen (PSA) responses, biochemical recurrence-free survival (BRFS), biochemical progression-free survival (BPFS), and overall survival (OS). Meta-regression and subgroup analyses were conducted to explore the heterogeneity. Sensitivity analysis was performed to assess the robustness of the results.
[RESULTS] A total of 71 studies comprising 9948 patients were included in this systematic review and meta-analysis. The pooled proportion of patients experiencing a management change following PSMA PET was 53% (95% CI: 48-58%). A decrease in serum PSA level was observed in 75% (95% CI: 65-85%) of patients. For survival outcomes, the pooled estimates for 1-, 2-, and 3-year biochemical recurrence-free survival (BRFS) were 62% (95% CI: 52-71%), 66% (95% CI: 55-77%), and 62% (95% CI: 46-78%), respectively. The corresponding estimates for biochemical progression-free survival (BPFS) were 77% (95% CI: 65-88%), 84% (95% CI: 71-97%), and 79% (95% CI: 61-96%), respectively.
[CONCLUSIONS] This meta-analysis suggests that PSMA PET-guided management is associated with favorable oncologic outcomes in men with biochemical recurrence, with over half of patients experiencing a change in management strategy and a substantial proportion demonstrating a biochemical response. Nevertheless, due to considerable heterogeneity across studies, these conclusions remain preliminary and require confirmation through more robust prospective evidence.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Analysis of overall survival in patients with second primary malignancies following with the first diagnosis of nonmetastatic prostate cancer: A study utilizing the Surveillance, Epidemiology, and End Results database.
- Cathepsins in prostate cancer: multifunctional regulators in tumor progression and therapeutic prospects-a narrative review.
- Dissecting tumor heterogeneity in colorectal cancer: uncovering the role of BCL2L1 cells through single-cell analysis.
- Comparative transcriptomic analysis reveals STAT3 as a candidate gene involved in aristolochic acid I-induced hepatorenal toxicity.
- METTL3-m6A-MALAT1 axis exacerbates the autophagy impairment and lipid accumulation in NAFLD by regulating miR-690.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Cost-Effectiveness of PSMA PET/CT as Single Procedure for Diagnosis and Staging High-Grade Prostate Cancer: A Single Center Experience.
- Non-invasive diagnosis strategy integrating PSMA PET/CT and mpMRI for patients with suspected prostate cancer: a multi-center study.
- PSMA-RADS 2.0: clinical validation and technical considerations for prostate-specific membrane antigen positron emission tomography/computed tomography image interpretation.
- Clinical application of PRIMARY score in diagnosing clinically significant prostate cancer: a comparative study using Ga-PSMA-11 and F-PSMA-1007 positron emission tomography/computed tomography.
- PSMA PET-guided intensification of postprostatectomy salvage radiotherapy for prostate cancer: a systematic review and meta-analysis.